董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Allen | 男 | Chairman of the Board | 62 | 22.50万 | 未持股 | 2020-10-21 |
| Alan Hirzel | 男 | Chief Executive Officer and Director | 51 | 159.55万 | 未持股 | 2020-10-21 |
| Michael Baldock | 男 | Chief Financial Officer and Director | 54 | 41.88万 | 未持股 | 2020-10-21 |
| Mara Aspinall | 女 | Director | 56 | 7.25万 | 未持股 | 2020-10-21 |
| Giles Kerr | 男 | Director | 59 | 7.79万 | 未持股 | 2020-10-21 |
| Louise Patten | 女 | Director | 64 | 8.25万 | 未持股 | 2020-10-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alan Hirzel | 男 | Chief Executive Officer and Director | 51 | 159.55万 | 未持股 | 2020-10-21 |
| Michael Baldock | 男 | Chief Financial Officer and Director | 54 | 41.88万 | 未持股 | 2020-10-21 |
董事简历
中英对照 | 中文 | 英文- Peter Allen
-
Peter Allen在2003年加入Haemonetics，担任其全球等离子体项目经理，并担任Donor Division经理。2008年3月，他被任命为首席营销官。2011年10月他被提升为全球等离子体总裁。加入Haemonetics之前，他是The Aethena Group（一个提供全球医疗服务的私人股本公司）的副总裁。从1998年到2001年，他在Syncor Internationa（放射性药物和综合医学影像服务的提供商）担任不同职位包括销售和肿瘤学业务的副总裁。之前，他在DataMedic, Inc，Enterprise Systems, Inc./HBOC和 Robertson Lowstuter, Inc担任销售、市场营销、和执行方面的主管级别的职位。他也曾在American Hospital Supply Corporation 和Baxter International, Inc.工作。
Peter Allen has served as a member of our board since June 2018. Mr. Allen is currently Non-Executive Chairman of Advanced Medical Solutions plc, Clinigen plc and privately owned Oxford Nanopore Technologies Ltd. He is a Non-Executive Director of Istesso Ltd. From 2015 to 2020 Mr. Allen served as the Chairman of Diurnal Group plc. From 2009 to 2012 Mr. Allen served as Chairman of Proximagen Neurosciences plc, from 2007 to 2013 he served as Chairman of ProStrakan Group plc, including as interim CEO from 2010 to 2011 and he served as CFO and Deputy CEO of Celltech Group plc from 1992 to 2004. Mr. Allen holds a B.A. in Accountancy and Law from the University of Kent. - Peter Allen在2003年加入Haemonetics，担任其全球等离子体项目经理，并担任Donor Division经理。2008年3月，他被任命为首席营销官。2011年10月他被提升为全球等离子体总裁。加入Haemonetics之前，他是The Aethena Group（一个提供全球医疗服务的私人股本公司）的副总裁。从1998年到2001年，他在Syncor Internationa（放射性药物和综合医学影像服务的提供商）担任不同职位包括销售和肿瘤学业务的副总裁。之前，他在DataMedic, Inc，Enterprise Systems, Inc./HBOC和 Robertson Lowstuter, Inc担任销售、市场营销、和执行方面的主管级别的职位。他也曾在American Hospital Supply Corporation 和Baxter International, Inc.工作。
- Peter Allen has served as a member of our board since June 2018. Mr. Allen is currently Non-Executive Chairman of Advanced Medical Solutions plc, Clinigen plc and privately owned Oxford Nanopore Technologies Ltd. He is a Non-Executive Director of Istesso Ltd. From 2015 to 2020 Mr. Allen served as the Chairman of Diurnal Group plc. From 2009 to 2012 Mr. Allen served as Chairman of Proximagen Neurosciences plc, from 2007 to 2013 he served as Chairman of ProStrakan Group plc, including as interim CEO from 2010 to 2011 and he served as CFO and Deputy CEO of Celltech Group plc from 1992 to 2004. Mr. Allen holds a B.A. in Accountancy and Law from the University of Kent.
- Alan Hirzel
-
Alan Hirzel自2014年9月以来担任我们的首席执行官，自2014年1月以来担任我们的董事会成员。加入ABCAM公司之前，他曾担任Bain&Company的合伙人，在那里他曾为全球高管和私人股本投资者提供增长战略、业绩改善和收购方面的建议。在他的职业生涯早期，Hirzel先生担任过各种职务，从康奈尔大学的生命科学研究员到卡夫食品公司的新产品开发研究。Hirzel先生拥有康奈尔大学（Cornell University）的学士学位，硕士学位和工商管理硕士学位。
Alan Hirzel has served as our Chief Executive Officer since September 2014 and as a member of our board since January 2014. Prior to joining Abcam, Mr. Hirzel was a partner at Bain & Company where he advised global executives and private equity investors on growth strategy, performance improvement and acquisitions. Early in his career, Mr. Hirzel worked in a variety of roles from life science researcher at Cornell University to new product development research at Kraft Foods. Mr. Hirzel holds BS, MS, and MBA degrees from Cornell University. - Alan Hirzel自2014年9月以来担任我们的首席执行官，自2014年1月以来担任我们的董事会成员。加入ABCAM公司之前，他曾担任Bain&Company的合伙人，在那里他曾为全球高管和私人股本投资者提供增长战略、业绩改善和收购方面的建议。在他的职业生涯早期，Hirzel先生担任过各种职务，从康奈尔大学的生命科学研究员到卡夫食品公司的新产品开发研究。Hirzel先生拥有康奈尔大学（Cornell University）的学士学位，硕士学位和工商管理硕士学位。
- Alan Hirzel has served as our Chief Executive Officer since September 2014 and as a member of our board since January 2014. Prior to joining Abcam, Mr. Hirzel was a partner at Bain & Company where he advised global executives and private equity investors on growth strategy, performance improvement and acquisitions. Early in his career, Mr. Hirzel worked in a variety of roles from life science researcher at Cornell University to new product development research at Kraft Foods. Mr. Hirzel holds BS, MS, and MBA degrees from Cornell University.
- Michael Baldock
-
Michael Baldock自2020年2月起担任我们的首席财务官，自2020年2月起担任董事会成员。从2008年11月至2020年1月，Baldock先生是独立财务咨询公司Ondra Partners的创始合伙人。在此之前，从2004年到2007年，他担任全球全能银行汇丰银行（HSBC plc）的董事总经理、梦百合全球主管和美洲投资银行业务主管。从2000年到2004年，他曾担任Lazard FR&232；res&Co.LLC（财务咨询和资产管理公司）的合伙人。Baldock先生还担任Jaws AcquisitionCorp.的非执行董事。Baldock先生在哈佛学院（Harvard College）获得社会研究学士学位。
Michael Baldock has served as our Chief Financial Officer since February 2020 and as a member of our board since February 2020. From November 2008 to January 2020 Mr. Baldock was a founding partner at Ondra Partners, an independent financial advisory firm. Prior to that, from 2004 to 2007 he was a Managing Director, Global Head of Healthcare and Head of Investment Banking, Americas for HSBC plc, a global universal bank. From 2000 to 2004 he was a Partner of Lazard Frères & Co. LLC, a financial advisory and asset management firm. Mr. Baldock also serves as a non-executive director of Jaws Acquisition Corp. Mr. Baldock received an A.B. in Social Studies from Harvard College. - Michael Baldock自2020年2月起担任我们的首席财务官，自2020年2月起担任董事会成员。从2008年11月至2020年1月，Baldock先生是独立财务咨询公司Ondra Partners的创始合伙人。在此之前，从2004年到2007年，他担任全球全能银行汇丰银行（HSBC plc）的董事总经理、梦百合全球主管和美洲投资银行业务主管。从2000年到2004年，他曾担任Lazard FR&232；res&Co.LLC（财务咨询和资产管理公司）的合伙人。Baldock先生还担任Jaws AcquisitionCorp.的非执行董事。Baldock先生在哈佛学院（Harvard College）获得社会研究学士学位。
- Michael Baldock has served as our Chief Financial Officer since February 2020 and as a member of our board since February 2020. From November 2008 to January 2020 Mr. Baldock was a founding partner at Ondra Partners, an independent financial advisory firm. Prior to that, from 2004 to 2007 he was a Managing Director, Global Head of Healthcare and Head of Investment Banking, Americas for HSBC plc, a global universal bank. From 2000 to 2004 he was a Partner of Lazard Frères & Co. LLC, a financial advisory and asset management firm. Mr. Baldock also serves as a non-executive director of Jaws Acquisition Corp. Mr. Baldock received an A.B. in Social Studies from Harvard College.
- Mara Aspinall
-
Mara Aspinall，2015年9月起，担任本公司董事。Aspinall女士是Allscripts梦百合Solutions Inc.、Castle Biosciences Inc.、Blue Cross Blue Shield Arizona Inc.、Orasure Technologies Inc.、Strateos先前的3Scan Inc.、Rainbird和Paradigm Diagnostics的董事。Aspinall女士是Bluestone Venture Partners的联合创始人兼董事总经理，以及Health Catalysts Group的首席执行官。此前，Aspinall女士是Ventana Medical Systems/Roche Tissue Diagnostics的总裁兼首席执行官。Aspinall女士在健赞公司（现为赛诺菲的一部分）工作了12年，担任Genzyme Genetics和Genzyme Pharmaceuticals的总裁。Aspinall女士是亚利桑那州立大学（Arizona State University）国际生物医学诊断学院（International School of Biomedical Diagnostics）的联合创始人，该学院是唯一致力于诊断学独立学科研究的机构。Aspinall女士还是美国医学和生物工程研究所（American Institute for Medical and Biological Engineering）的研究员。Aspinall女士拥有塔夫茨大学（Tufts University）国际关系学士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
Mara Aspinall will serve on our board of directors following this offering. Ms. Aspinall has been a Managing Director and Co-Founder of BlueStone Venture Partners, a venture fund investing in life sciences technology companies in the US Southwest, since 2017 and has been Managing Director of the Health Catalysts Group, a consulting firm dedicated to the growth of health information technology and diagnostics firms, since 2014. Ms. Aspinall previously served as Executive Chairman of GenePeeks from January 2015 to May 2018. She currently serves on the Board of Directors of Abcam plc Nasdaq: ABCM since 2015 Allscripts Healthcare Solutions Inc. (Nasdaq: MDRX) since 2017 Castle Biosciences Inc (Nasdaq: CSTL) since 2015 OraSure Technologies Inc (Nasdaq: OSUR) since 2017 and Blue Cross Blue Shield Arizona since 2015. Ms. Aspinall currently sits on the Audit and Risk Committee, the Nomination Committee and is interim Chair of the Remuneration Committee for Abcam plc, sits on the Audit Committee of Allscripts Healthcare Solutions Inc., sits on the Audit Committee and is Chair of the Nominating and Corporate Governance Committee of Castle Biosciences Inc, and sits on the Compensation Committee and is Chair of the Audit Committee of OraSure Technologies Inc. She previously served on the Health and Human Services Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) in the Obama and Bush administrations. Ms. Aspinall was the President and CEO of Ventana Medical Systems, a billion-dollar division of The Roche Group (now Roche Tissue Diagnostics), from 2011 to 2014. Previously, she spent 13 years at Genzyme Corporation from 1997 to 2009 where she served as President of Genzyme Genetics and Genzyme Pharmaceuticals. She transformed Genzyme Genetics from a small specialized player to one of the leading laboratories in the country, prior to its sale to LabCorp for $925 million. Ms. Aspinall has a B.A. from Tufts University and an M.B.A. from Harvard Business School. - Mara Aspinall，2015年9月起，担任本公司董事。Aspinall女士是Allscripts梦百合Solutions Inc.、Castle Biosciences Inc.、Blue Cross Blue Shield Arizona Inc.、Orasure Technologies Inc.、Strateos先前的3Scan Inc.、Rainbird和Paradigm Diagnostics的董事。Aspinall女士是Bluestone Venture Partners的联合创始人兼董事总经理，以及Health Catalysts Group的首席执行官。此前，Aspinall女士是Ventana Medical Systems/Roche Tissue Diagnostics的总裁兼首席执行官。Aspinall女士在健赞公司（现为赛诺菲的一部分）工作了12年，担任Genzyme Genetics和Genzyme Pharmaceuticals的总裁。Aspinall女士是亚利桑那州立大学（Arizona State University）国际生物医学诊断学院（International School of Biomedical Diagnostics）的联合创始人，该学院是唯一致力于诊断学独立学科研究的机构。Aspinall女士还是美国医学和生物工程研究所（American Institute for Medical and Biological Engineering）的研究员。Aspinall女士拥有塔夫茨大学（Tufts University）国际关系学士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
- Mara Aspinall will serve on our board of directors following this offering. Ms. Aspinall has been a Managing Director and Co-Founder of BlueStone Venture Partners, a venture fund investing in life sciences technology companies in the US Southwest, since 2017 and has been Managing Director of the Health Catalysts Group, a consulting firm dedicated to the growth of health information technology and diagnostics firms, since 2014. Ms. Aspinall previously served as Executive Chairman of GenePeeks from January 2015 to May 2018. She currently serves on the Board of Directors of Abcam plc Nasdaq: ABCM since 2015 Allscripts Healthcare Solutions Inc. (Nasdaq: MDRX) since 2017 Castle Biosciences Inc (Nasdaq: CSTL) since 2015 OraSure Technologies Inc (Nasdaq: OSUR) since 2017 and Blue Cross Blue Shield Arizona since 2015. Ms. Aspinall currently sits on the Audit and Risk Committee, the Nomination Committee and is interim Chair of the Remuneration Committee for Abcam plc, sits on the Audit Committee of Allscripts Healthcare Solutions Inc., sits on the Audit Committee and is Chair of the Nominating and Corporate Governance Committee of Castle Biosciences Inc, and sits on the Compensation Committee and is Chair of the Audit Committee of OraSure Technologies Inc. She previously served on the Health and Human Services Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) in the Obama and Bush administrations. Ms. Aspinall was the President and CEO of Ventana Medical Systems, a billion-dollar division of The Roche Group (now Roche Tissue Diagnostics), from 2011 to 2014. Previously, she spent 13 years at Genzyme Corporation from 1997 to 2009 where she served as President of Genzyme Genetics and Genzyme Pharmaceuticals. She transformed Genzyme Genetics from a small specialized player to one of the leading laboratories in the country, prior to its sale to LabCorp for $925 million. Ms. Aspinall has a B.A. from Tufts University and an M.B.A. from Harvard Business School.
- Giles Kerr
-
Giles Kerr，他一直担任Abcam Plc的董事（2018年12月以来）。他目前是Arix Bioscience plc, Senior plc和Oxford Sciences Innovation的非执行董事，也是Paypoint plc的主席。自1990年以来，Kerr先生在Amersham plc担任各种越来越高级的职务，包括1997年至2004年该公司被GE Healthcare收购时的首席财务官和董事会成员。在Amersham任职之前，他是Arthur Andersen & Co.的国家合伙人。2005年至2018年，他是牛津大学（University of Oxford）的财务总监，此前是Victrex plc、BTG plc、Quanta透析技术和Elan Corporation的董事。他持有the University of York的经济学学士学位。
Giles Kerr has served as a member of our board since December 2018. Mr. Kerr is currently a Non-Executive Director of Arix Bioscience plc, Senior plc and Oxford Sciences Innovation and is the Chairman of Paypoint plc. Since 1990 Mr. Kerr has served in a variety of increasingly senior roles at Amersham plc, including Chief Financial Officer and a board member from 1997 to 2004 when the company was acquired by GE Healthcare. Prior to his role at Amersham, Mr. Kerr was a National Partner with Arthur Andersen & Co. Mr. Kerr was Director of Finance of the University of Oxford from 2005 until 2018 and was previously a Director of Victrex plc, BTG plc, Quanta Dialysis Technologies and Elan Corporation Inc. Mr. Kerr holds a B.A. in Economics from the University of York. - Giles Kerr，他一直担任Abcam Plc的董事（2018年12月以来）。他目前是Arix Bioscience plc, Senior plc和Oxford Sciences Innovation的非执行董事，也是Paypoint plc的主席。自1990年以来，Kerr先生在Amersham plc担任各种越来越高级的职务，包括1997年至2004年该公司被GE Healthcare收购时的首席财务官和董事会成员。在Amersham任职之前，他是Arthur Andersen & Co.的国家合伙人。2005年至2018年，他是牛津大学（University of Oxford）的财务总监，此前是Victrex plc、BTG plc、Quanta透析技术和Elan Corporation的董事。他持有the University of York的经济学学士学位。
- Giles Kerr has served as a member of our board since December 2018. Mr. Kerr is currently a Non-Executive Director of Arix Bioscience plc, Senior plc and Oxford Sciences Innovation and is the Chairman of Paypoint plc. Since 1990 Mr. Kerr has served in a variety of increasingly senior roles at Amersham plc, including Chief Financial Officer and a board member from 1997 to 2004 when the company was acquired by GE Healthcare. Prior to his role at Amersham, Mr. Kerr was a National Partner with Arthur Andersen & Co. Mr. Kerr was Director of Finance of the University of Oxford from 2005 until 2018 and was previously a Director of Victrex plc, BTG plc, Quanta Dialysis Technologies and Elan Corporation Inc. Mr. Kerr holds a B.A. in Economics from the University of York.
- Louise Patten
-
Louise Patten，2014年3月起，担任本公司董事。Patten女士目前是Bain&Company的高级顾问，也是Arthur J Gallagher UK Limited，Arthur J Gallagher Holdings（UK）Limited和Arthur J Gallagher Insurance Brokers Limited的非执行董事。Patten女士的职业生涯始于企业和投资银行业务，随后进入管理咨询公司，并成为希尔顿集团（The Hilton Group）董事会董事。自那时起，Patten女士在包括The Retailers Marks&Spencer plc，GUS plc和Somerfield plc在内的组织担任了20多年的非执行董事，高级独立董事，薪酬委员会主席和公司董事长。Patten女士拥有牛津大学（Oxford University）硕士学位。
Louise Patten has served as a member of our board since March 2014. Ms. Patten is currently a Senior Advisor to Bain & Company and a Non-Executive Director of Arthur J Gallagher UK Limited, Arthur J Gallagher Holdings (UK) Limited and Arthur J Gallagher Insurance Brokers Limited. Having started her career in corporate and investment banking, Ms. Patten moved into management consultancy and became a Board Director of the Hilton Group. Since then, Ms. Patten has served on a succession of multi-national listed company boards for more than 20 years as a non-executive director, a senior independent director, a remuneration committee chairman and a company chairman at organizations including the retailers Marks & Spencer plc, GUS plc and Somerfield plc. Ms. Patten holds a M.A. from Oxford University. - Louise Patten，2014年3月起，担任本公司董事。Patten女士目前是Bain&Company的高级顾问，也是Arthur J Gallagher UK Limited，Arthur J Gallagher Holdings（UK）Limited和Arthur J Gallagher Insurance Brokers Limited的非执行董事。Patten女士的职业生涯始于企业和投资银行业务，随后进入管理咨询公司，并成为希尔顿集团（The Hilton Group）董事会董事。自那时起，Patten女士在包括The Retailers Marks&Spencer plc，GUS plc和Somerfield plc在内的组织担任了20多年的非执行董事，高级独立董事，薪酬委员会主席和公司董事长。Patten女士拥有牛津大学（Oxford University）硕士学位。
- Louise Patten has served as a member of our board since March 2014. Ms. Patten is currently a Senior Advisor to Bain & Company and a Non-Executive Director of Arthur J Gallagher UK Limited, Arthur J Gallagher Holdings (UK) Limited and Arthur J Gallagher Insurance Brokers Limited. Having started her career in corporate and investment banking, Ms. Patten moved into management consultancy and became a Board Director of the Hilton Group. Since then, Ms. Patten has served on a succession of multi-national listed company boards for more than 20 years as a non-executive director, a senior independent director, a remuneration committee chairman and a company chairman at organizations including the retailers Marks & Spencer plc, GUS plc and Somerfield plc. Ms. Patten holds a M.A. from Oxford University.
高管简历
中英对照 | 中文 | 英文- Alan Hirzel
Alan Hirzel自2014年9月以来担任我们的首席执行官，自2014年1月以来担任我们的董事会成员。加入ABCAM公司之前，他曾担任Bain&Company的合伙人，在那里他曾为全球高管和私人股本投资者提供增长战略、业绩改善和收购方面的建议。在他的职业生涯早期，Hirzel先生担任过各种职务，从康奈尔大学的生命科学研究员到卡夫食品公司的新产品开发研究。Hirzel先生拥有康奈尔大学（Cornell University）的学士学位，硕士学位和工商管理硕士学位。
Alan Hirzel has served as our Chief Executive Officer since September 2014 and as a member of our board since January 2014. Prior to joining Abcam, Mr. Hirzel was a partner at Bain & Company where he advised global executives and private equity investors on growth strategy, performance improvement and acquisitions. Early in his career, Mr. Hirzel worked in a variety of roles from life science researcher at Cornell University to new product development research at Kraft Foods. Mr. Hirzel holds BS, MS, and MBA degrees from Cornell University.- Alan Hirzel自2014年9月以来担任我们的首席执行官，自2014年1月以来担任我们的董事会成员。加入ABCAM公司之前，他曾担任Bain&Company的合伙人，在那里他曾为全球高管和私人股本投资者提供增长战略、业绩改善和收购方面的建议。在他的职业生涯早期，Hirzel先生担任过各种职务，从康奈尔大学的生命科学研究员到卡夫食品公司的新产品开发研究。Hirzel先生拥有康奈尔大学（Cornell University）的学士学位，硕士学位和工商管理硕士学位。
- Alan Hirzel has served as our Chief Executive Officer since September 2014 and as a member of our board since January 2014. Prior to joining Abcam, Mr. Hirzel was a partner at Bain & Company where he advised global executives and private equity investors on growth strategy, performance improvement and acquisitions. Early in his career, Mr. Hirzel worked in a variety of roles from life science researcher at Cornell University to new product development research at Kraft Foods. Mr. Hirzel holds BS, MS, and MBA degrees from Cornell University.
- Michael Baldock
Michael Baldock自2020年2月起担任我们的首席财务官，自2020年2月起担任董事会成员。从2008年11月至2020年1月，Baldock先生是独立财务咨询公司Ondra Partners的创始合伙人。在此之前，从2004年到2007年，他担任全球全能银行汇丰银行（HSBC plc）的董事总经理、梦百合全球主管和美洲投资银行业务主管。从2000年到2004年，他曾担任Lazard FR&232；res&Co.LLC（财务咨询和资产管理公司）的合伙人。Baldock先生还担任Jaws AcquisitionCorp.的非执行董事。Baldock先生在哈佛学院（Harvard College）获得社会研究学士学位。
Michael Baldock has served as our Chief Financial Officer since February 2020 and as a member of our board since February 2020. From November 2008 to January 2020 Mr. Baldock was a founding partner at Ondra Partners, an independent financial advisory firm. Prior to that, from 2004 to 2007 he was a Managing Director, Global Head of Healthcare and Head of Investment Banking, Americas for HSBC plc, a global universal bank. From 2000 to 2004 he was a Partner of Lazard Frères & Co. LLC, a financial advisory and asset management firm. Mr. Baldock also serves as a non-executive director of Jaws Acquisition Corp. Mr. Baldock received an A.B. in Social Studies from Harvard College.- Michael Baldock自2020年2月起担任我们的首席财务官，自2020年2月起担任董事会成员。从2008年11月至2020年1月，Baldock先生是独立财务咨询公司Ondra Partners的创始合伙人。在此之前，从2004年到2007年，他担任全球全能银行汇丰银行（HSBC plc）的董事总经理、梦百合全球主管和美洲投资银行业务主管。从2000年到2004年，他曾担任Lazard FR&232；res&Co.LLC（财务咨询和资产管理公司）的合伙人。Baldock先生还担任Jaws AcquisitionCorp.的非执行董事。Baldock先生在哈佛学院（Harvard College）获得社会研究学士学位。
- Michael Baldock has served as our Chief Financial Officer since February 2020 and as a member of our board since February 2020. From November 2008 to January 2020 Mr. Baldock was a founding partner at Ondra Partners, an independent financial advisory firm. Prior to that, from 2004 to 2007 he was a Managing Director, Global Head of Healthcare and Head of Investment Banking, Americas for HSBC plc, a global universal bank. From 2000 to 2004 he was a Partner of Lazard Frères & Co. LLC, a financial advisory and asset management firm. Mr. Baldock also serves as a non-executive director of Jaws Acquisition Corp. Mr. Baldock received an A.B. in Social Studies from Harvard College.